NovAccess Global Announces Uplisting to OTCQB
NovAccess Global Announces Uplisting to OTCQB
CLEVELAND, OH / ACCESSWIRE / August 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the trading of its common shares has been upgraded to the OTC Markets Group's OTCQB® platform from the OTC Pink Market. The Company's ticker symbol remains the same.
俄亥俄州克利夫兰/ACCESSWIRE/2022年8月10日/为脑瘤患者开发新型免疫疗法的生物医药公司NovAccess Global Inc.(场外交易市场代码：XSNX)今天宣布，其普通股的交易已从场外粉色市场升级为场外交易市场集团的场外交易市场®平台。该公司的股票代码保持不变。
The OTCQB listing required the completion and submission of financial reporting with the Securities & Exchange Commission including two years of trailing audited financial results, an expanded Board of Directors which includes the requisite number of independent directors, and an annual verification and management certification process along with other administrative requirements.
OTCQB上市要求完成并向美国证券交易委员会提交财务报告，包括两年的跟踪审计财务结果、扩大的董事会(包括必要数量的独立董事)、年度核查和管理认证程序以及其他行政要求。
"The uplisting to OTCQB is an exciting milestone for NovAccess Global and marks another accomplishment in the slate of corporate initiatives we set out to achieve this year," said, the Company's Chief Executive Officer Dr. Dwain K. Irvin. "Beyond the steps taken a few months ago to partially recapitalize the company, last month we announced a critical submission for our lead drug candidate TLR-AD1 as the cornerstone of our platform for novel immunotherapy for brain tumor patients. The uplisting process provides added investment community visibility and transparency as we continue to execute on our plan that we believe will ultimately lead to enhancing value for our shareholders."
该公司首席执行官德温·K·欧文博士说：“对NovAccess Global来说，OTCQB的升迁是一个令人兴奋的里程碑，标志着我们今年计划实现的一系列企业计划中的又一项成就。除了几个月前采取的对公司进行部分资本重组的措施外，上个月我们宣布了对我们的主要候选药物TLR-AD1的关键提交，作为我们针对脑瘤患者的新型免疫疗法平台的基石。随着我们继续执行我们的计划，我们相信这最终将为我们的股东带来更高的价值，这一上升过程为投资界提供了更多的可见度和透明度。“
About NovAccess Global
关于NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global是一家加速新型癌症诊断和治疗的生物医药公司。我们的目标是发现、开发和向市场推出新颖和创新的药物和医疗设备，以提高癌症和神经科患者的护理质量。
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
NovAccess Global目前正在开发一种癌症疫苗疗法，以增强患者对脑瘤的免疫反应。我们公司有一种新的免疫治疗方法来治疗患有胶质母细胞瘤的脑肿瘤患者，胶质母细胞瘤是最常见的成人脑瘤，确诊后中位生存期为15个月。我们的专利技术旨在将基于树突状细胞的免疫治疗方法与Toll样受体(TLR)佐剂的独特组合TLR-AD1相结合，以帮助促进针对患者肿瘤的增强免疫反应。我们的平台技术专注于通过利用患者肿瘤特有的抗原来增强患者的免疫细胞，以对抗他们独特的癌症。这是一项有意义的技术，可以显著提高许多脑瘤患者的生活质量和预后。欲了解更多信息，请访问novacesslobal.com。
Forward-Looking Statement
前瞻性陈述
This email and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
本电子邮件及其附件包含《1933年证券法》(经修订)第27A节和《1934年证券交易法》(经修订)第21E节所指的“前瞻性陈述”，此类前瞻性陈述是根据1995年“私人证券诉讼改革法”的安全港条款作出的。“前瞻性陈述”描述未来的预期、计划、结果或战略，通常以“可能”、“未来”、“计划”或“计划”、“将”或“应该”、“预期”、“预期”、“草案”、“最终”或“预计”等词语开头。请注意，此类陈述会受到大量风险和不确定因素的影响，这些风险和不确定性可能会导致未来的情况、事件或结果与前瞻性陈述中预测的情况、事件或结果大不相同，包括由于各种因素，实际结果可能与前瞻性陈述中预测的结果大不相同的风险，以及公司向证券交易委员会和/或场外交易市场公司提交的披露或文件中确定的其他风险。请进一步提醒您，细价股和NovAccess，Inc.等较小公司的股票本质上是不稳定和有风险的，除非投资者能够承受全部投资的损失，否则任何投资者都不应购买这种股票。公司没有义务更新任何前瞻性陈述，以反映事件或情况发生之后的情况。
Investor Relations Contact:
投资者关系联系人：
Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com
乔丹·达罗
Darrow Associates
631-766-4528
邮箱：jdarrow@darrowir.com
SOURCE: NovAccess Global Inc.
资料来源：NovAccess Global Inc.
译文内容由第三方软件翻译。